Design of Hybrid Molecules for Drug Development

Design of Hybrid Molecules for Drug Development reviews the principles, advantages, and limitations involved with designing these groundbreaking compounds. Beginning with an introduction to hybrid molecule design and background as to their need, the book goes on to explore a range of important hybrids, with hybrids containing natural products, molecules containing NO- and H2S-donors, dual-acting compounds acting as receptor ligands and enzyme inhibitors, and the design of photoresponsive drugs all discussed.

Drawing on practical case studies, the hybridization of molecules for development as treatments for a number of key diseases is then outlined, including the design of hybrids for Alzheimer's, cancer, and malaria.

With its cutting-edge reviews of breaking developments in this exciting field, the book offers a novel approach for all those working in the design, development, and administration of drugs for a range of debilitating disorders.

• Highlights an approach unimpaired by the limitations of the classical search for lead structures - one of the core problems in modern drug development processes, making the content of high relevance for both academic and non-academic drug development processes
• Pulls together research and design techniques in a novel way to give researchers the best possible platform from which to review the approaches and techniques applied
• Compares the advantages and disadvantages of these compounds
• Includes the very latest developments, such as photoactivatable and photo-responsive drugs

Following a number of years as a medicinal chemistry lecturer and research scientist at institutes including Regensburg University Germany, Queens University Belfast UK, and Harvard Medical School USA, Michael Decker is currently Professor of Pharmaceutical and Medicinal Chemistry at the University Würzburg’s Institute of Pharmacy and Food Chemistry. His predominant focus is on the design of novel therapeutic compounds for the treatment of Alzheimer’s disease, which has led his group to a particular interest in the design of hybrid molecules.

Contributor to 75 publications and 1 patent, he is a spokesperson of the International Doctorate Program “Receptor Dynamics: Emerging paradigms for novel drugs” of the “Elite Network of Bavaria” (2014 to 2022) and is very actively engaged with the chemistry community